6-K
Grifols SA (GRFS)
UNITED STATESSECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2024
Commission File No. 001-35193
Grifols, S.A.
(Translation of registrant’s name into English)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Grifols, S.A.
TABLE OF CONTENTS
| Item | Sequential Page Number |
|---|---|
| 1. Other<br> Relevant Information, dated April 4, 2024 | 1 |
In accordance with the provisions of article 227 of Law 6/2023 of 17 March on Securities Markets and Investment Services, Grifols, S.A. ("Grifols" or the "Company") hereby announces the following.
OTHERRELEVANT INFORMATION
In reference to the report published by the Spanish National Securities Market Commission ("CNMV") on 21 March 2024, Grifols presents in this report the information requested and wishes to state its full commitment to comply with all regulations and standards in force to guarantee the transparency and integrity of present and future financial information.
Grifols also undertakes to implement all the measures mentioned below, as well as any additional measures necessary to ensure the quality of the information provided to financial markets and investors and the strictest compliance with the guidelines and recommendations established by the European Securities and Markets Authority ("ESMA") and the CNMV.
A) Relevance of financial measures
Grifols' financial statements are prepared in accordance with EU-IFRS and other provisions of the applicable financial reporting framework and include other measures prepared in accordance with the group's financial reporting model called Alternative Performance Measures ("APMs") as defined in the guidelines issued by ESMA. The APMs are used by Grifols' management to assess the group's business performance and cash flows in making operational and strategic decisions and are, therefore, useful information for investors and other stakeholders.
Grifols is committed to giving equal weight to both financial measures and APMs presented in the company's financial publications.
B) Reduction in the number of measures used to reflect EBITDA (APM)
In order to simplify and improve clarity in the presentation of financial information, the company will reduce the number of measures used to reflect EBITDA in its earnings reports to two: consolidated EBITDA on a profit and loss basis and consolidated adjusted EBITDA. In this respect, Grifols will report the aforementioned EBITDAs on a consolidated basis without differentiating whether or not the figures corresponding to Biotest are included.
These two EBITDA measures will be used as measures of the company's performance and will serve the purpose of providing better comparability of Grifols' performance and profitability over time, as well as in relation to other comparable companies.
Consolidated EBITDA on a profit and loss basis is defined as EBIT excluding depreciation of property, plant, and equipment, depreciation of right-of-use assets, amortisation of intangible assets, and impairment of property, plant, and equipment, right-of-use assets, and intangible assets
Adjusted consolidated EBITDA is defined as consolidated EBITDA on a profit and loss basis plus: (i) extraordinary, unusual or non-recurring charges and expenses; (ii) any other non-recurring costs of doing business; minus (iii) non-recurring revenues and earnings.
1
To reinforce the clarity of the information provided on APMs, Grifols undertakes to introduce definitions and detailed explanations of them, explaining their relevance and usefulness. In addition, the APMs will be identified with their respective label or specific note, which will reflect their calculation bases. In addition, the consistency over time of all APMs used in our financial reporting will be ensured.
In addition to all the periodic information that Grifols publishes on the APMs and which form part of the quarterly results presentation, Grifols will henceforth publish a complementary document including the definition, relevance of use and reconciliation with the financial statements of all the APMs used, which will be publicly available in the "Investors" section of the Grifols website.
C) Use of non-recurring, infrequent, or unusual items
Grifols undertakes to limit the use of non-recurring, infrequent or unusual items to specific cases, providing details and justification for the use of such items.
Where such items are used, particular emphasis shall be placed on including items of a non-recurring nature which have not had an impact in prior periods and are not expected to have an impact in the future. This will ensure that the APMs accurately reflect the reality of the entity's business and facilitate accurate interpretation and analysis by investors and other interested parties.
D) Cost savings adjustments and operational improvements
With regard to adjustments for cost savings, operational improvements, and synergies made to consolidated EBITDA under the Credit Agreement, we confirm that this financial measure is not used as an alternative measure of entity performance and should, therefore, not be interpreted as such.
In future public financial reporting, Grifols will clarify that integrating adjustments based on expectations means that these measures project future scenarios rather than represent current financial results. This distinction will be explicitly communicated to ensure all stakeholders understand that such measures are not indicators of the entity's financial performance or results.
Finally, it should be noted that when the company reports an adjusted financial figure, it should specify in its name that it is an adjusted measure so that an investor can distinguish it from an unadjusted measure or ratio. Additionally, it should disclose the financial measure or ratio calculated with measures directly extracted from the financial statements without adjustment.
E) Breakdown of EBITDA and Net Debt
The company undertakes to disclose the consolidated EBITDA ratios according to profit and loss (APM) and adjusted EBITDA (APM), adding all the necessary notes. Hence, investors have all the information available. In this way, the reconciliation of the net financial debt (APM) to the net balance sheet debt reflected in the company's financial statements will be broken down as detailed below.
It should be noted that we will continue to report the debt-to-equity ratio under the Credit Agreement in the appendices to our quarterly earnings presentations and other financial publications. The EBITDA included in this calculation is a measure that serves as a benchmark for the company's financial leverage ratio under the Credit Agreement and is, therefore, not considered a APM as it is not intended to reflect the business's financial performance.
2
Consolidated EBITDAas per profit and loss (APM) and Net Debt As per Balance Sheet
| Thousands<br> of Euros | 2022 | 2023 | ||||
|---|---|---|---|---|---|---|
| Consolidated<br> result for the year | 208.279 | 59.315 | ||||
| Result<br> of entities accounted for using the equity method | 1.483 | 923 | ||||
| Financial<br> result | 442.941 | 574.458 | ||||
| Income<br> tax expense | 90.111 | 43.349 | ||||
| Profit<br> attributable to non-controlling interests | 62.867 | 121.354 | ||||
| Amortisation<br> and depreciation | 415.338 | 451.759 | ||||
| Consolidated EBITDA according to P&L | **** | 1.221.019 | **** | 1.251.157 | ||
| Thousands<br> of Euros | 2022 | 2023 | ||||
| --- | --- | --- | --- | --- | --- | --- |
| Cash<br> and cash equivalents | (547.979 | ) | (529.577 | ) | ||
| Leasing<br> liabilities (leases of real estate of plasma donation centres) | 1.016.944 | 1.111.329 | ||||
| Loans and<br> other financial liabilities | 9.739.304 | 9.945.889 | ||||
| Total Balance Sheet Net Debt | **** | 10.208.270 | **** | **** | 10.527.641 | **** |
| Leverage ratio | **** | 8,4 | **** | **** | 8,4 | **** |
ConsolidatedEBITDA under Credit Agreement and Net Financial Debt under Credit Agreement (APM)
| Thousands<br> of Euros | 2022 | 2023 | ||||
|---|---|---|---|---|---|---|
| Consolidated result<br> for the year | 208.279 | 59.315 | ||||
| Result of entities accounted<br> for using the equity method | 1.483 | 923 | ||||
| Financial result | 442.941 | 574.458 | ||||
| Income tax expense | 90.111 | 43.349 | ||||
| Profit attributable to non-controlling<br> interests | 62.867 | 121.354 | ||||
| Amortisation and depreciation | 415.338 | 451.759 | ||||
| Consolidated EBITDA according to P&L | **** | 1.221.019 | **** | **** | 1.251.157 | **** |
| Impact IFRS16- Finance Leases<br> (leases of plasma donation centre properties) | (99.989 | ) | (101.784 | ) | ||
| Restructuring costs | 36.074 | 158.952 | ||||
| Transaction costs | 5.930 | 47.992 | ||||
| Integration costs | 24.171 | 0 | ||||
| Other non-recurring events | 0 | (6.636 | ) | |||
| Cost savings, operational improvements<br> and synergies in one implementation rate | 100.000 | 134.968 | ||||
| Consolidated EBITDA under Credit Agreement | **** | 1.287.203 | **** | **** | 1.484.650 | **** |
| Thousands<br> of Euros | 2022 | 2023 | ||||
| --- | --- | --- | --- | --- | --- | --- |
| Cash and cash equivalents | (547.979 | ) | (529.577 | ) | ||
| Leasing liabilities (leases<br> of real estate of plasma donation centres) | 1.016.944 | 1.111.329 | ||||
| Loans and other financial liabilities | 9.739.304 | 9.945.889 | ||||
| Total Balance Sheet Net Debt | **** | 10.208.270 | **** | **** | 10.527.641 | **** |
| Impact IFRS16- Finance Leases<br> (leases of plasma donation centre properties) | (1.016.944 | ) | (1.111.329 | ) | ||
| Total Net Financial Debt according to Credit Agreement | **** | 9.191.326 | **** | **** | 9.416.312 | **** |
| Leverage ratio | **** | 7,1 | **** | **** | 6,3 | **** |
3
The main differences between the leverage ratio according to the Credit Agreement and the leverage ratio according to the financial statements (P&L and Balance Sheet) in 2023 are due to;
| i. | 234<br> million, in accordance with the Credit Agreement, corresponding to: (i) extraordinary, unusual<br> or non-recurring expenses; (ii) cost savings and operational improvements for the next 12<br> months (limited to 10% of Consolidated EBITDA under the Credit Agreement); and (iii) the<br> exclusion of the leasing expense. |
|---|---|
| ii. | the<br> exclusion of the debt associated with the leasing contracts (leases of the plasma donation<br> centers’ real estate) for a total of 1,111 million euros, in accordance with the Credit<br> Agreement. |
| --- | --- |
F)Breakdown of EBITDA and Net Financial Debt of relevant entities with non-controlling interests
Below are the consolidated figures for Grifols' consolidated EBITDA according to profit and loss (APM) and the net financial debt of the most relevant entities in which Grifols has non-controlling interests, following the parameters used for the company's debt calculations, by the requirements of the Credit Agreement with the lenders and the Indenture, and which have been applied consistently.
In this regard, we confirm our future commitment to provide a detailed breakdown of EBITDA and net financial debt for those relevant entities in which we have non-controlling interests.
4
2022
| Thousands of Euros | GDS Group | **** | Biotest Group | **** | BPC | **** | Haema | **** | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit after tax from continuing operations | 140.678 | (18.002 | ) | 30.086 | (4.858 | ) | ||||||
| Income tax expense | 39.897 | (690 | ) | 2.747 | (1.459 | ) | ||||||
| Financial result | (45.420 | ) | 11.327 | (5.874 | ) | (1.086 | ) | |||||
| Amortisation and depreciation | 50.791 | 30.535 | 13.213 | 8.158 | ||||||||
| Consolidated EBITDA according to P&L | 185.947 | **** | 23.171 | **** | 40.172 | **** | 755 | **** | ||||
| Impact IFRS16- Finance Leases (leases of plasma donation centre<br> properties) | (2.412 | ) | (3.780 | ) | (5.492 | ) | (4.115 | ) | ||||
| Restructuring costs | 1.117 | 0 | 118 | 3.049 | ||||||||
| Other non-recurring items | 0 | 0 | 0 | |||||||||
| Consolidated EBITDA under Credit Agreement | 184.652 | **** | 19.391 | **** | 34.798 | **** | (311 | ) | ||||
| % of non-controlling interest | 33,2 | % | 29,8 | % | 100,0 | % | 100,0 | % | ||||
| Consolidated EBITDA according to Credit Agreement noncontrolling interest | 61.323 | **** | 5.778 | **** | 34.798 | **** | (311 | ) | ||||
| Thousands of Euros | GDS<br> Group | Biotest<br><br>Group | BPC | Haema | ||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash and cash equivalents | (540 | ) | (116.642 | ) | (7.677 | ) | (19.906 | ) | ||||
| Financial assets/liabilities with Grifols | (949.951 | ) | 329.192 | 0 | 0 | |||||||
| Leasing liabilities (leases of real estate of plasma donation centres) | 13.573 | 28.974 | 57.092 | 12.796 | ||||||||
| Loans and other financial liabilities | 6.082 | 293.158 | 0 | 0 | ||||||||
| Total Balance Sheet Net Debt | **** | (930.836 | ) | **** | 534.682 | **** | **** | 49.415 | **** | **** | (7.110 | ) |
| Impact IFRS16- Finance Leases (leases of plasma donation centre properties) | (13.573 | ) | (28.974 | ) | (57.092 | ) | (12.796 | ) | ||||
| Total Net Financial Debt according to Credit Agreement | **** | (944.409 | ) | **** | 505.709 | **** | **** | (7.677 | ) | **** | (19.906 | ) |
| Total Net Financial Debt according to Credit Agreement noncontrolling interest | **** | (313.638 | ) | **** | 150.701 | **** | **** | (7.677 | ) | **** | (19.906 | ) |
5
2023
| Thousands of Euros | GDS<br><br> Group | Biotest<br><br> Group | BPC | Haema | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit after tax from continuing operations | 119.453 | (74.795 | ) | 67.892 | 24.936 | |||||||
| Income tax expense | 41.939 | (49.092 | ) | 9.005 | 4.653 | |||||||
| Financial result | (62.947 | ) | 48.088 | (14.310 | ) | (5.026 | ) | |||||
| Amortisation and depreciation | 52.997 | 62.292 | 9.839 | 7.965 | ||||||||
| Consolidated EBITDA according to P&L | 151.442 | (13.507 | ) | 72.426 | 32.528 | |||||||
| Impact IFRS16- Finance Leases (leases of plasma donation centre<br> properties) | (1.763 | ) | (5.921 | ) | (5.525 | ) | (5.327 | ) | ||||
| Restructuring costs | 0 | 0 | 1.706 | 0 | ||||||||
| Other non-recurring items | (13.599 | ) | 10.400 | 0 | ||||||||
| Consolidated EBITDA under Credit Agreement | 136.079 | (9.028 | ) | 68.608 | 27.201 | |||||||
| % of non-controlling interest | 33,2 | % | 29,8 | % | 100,0 | % | 100,0 | % | ||||
| Consolidated EBITDA according to Credit Agreement noncontrolling<br> interest | 45.192 | (2.690 | ) | 68.608 | 27.201 | |||||||
| Thousands of Euros | GDS<br> Group | Biotest<br><br>Group | BPC | Haema | ||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash and cash equivalents | (972 | ) | (108.080 | ) | (4.803 | ) | (14.817 | ) | ||||
| Financial assets/liabilities with Grifols | (941.499 | ) | 336.548 | 0 | 0 | |||||||
| Leasing liabilities (leases of real estate of plasma donation centres) | 13.870 | 57.881 | 53.788 | 12.749 | ||||||||
| Loans and other financial liabilities | 4.285 | 302.503 | 0 | 0 | ||||||||
| Total Balance Sheet Net Debt | (924.315 | ) | 588.852 | 48.984 | (2.068 | ) | ||||||
| Impact IFRS16- Finance Leases (leases of plasma donation centre properties) | (13.870 | ) | (57.881 | ) | (53.788 | ) | (12.749 | ) | ||||
| Total Net Financial Debt according to Credit Agreement | (938.185 | ) | 530.970 | (4.803 | ) | (14.817 | ) | |||||
| Total Net Financial Debt according to Credit Agreement non-controlling interest | (311.571 | ) | 158.229 | (4.803 | ) | (14.817 | ) |
G) Controlprocedures
Grifols will strengthen its control procedures to minimise the possibility of errors. To this end, we are committed to establishing a new level of review by the company's internal control department.
These procedures will be subject to strict reporting and disclosure controls. They will be specifically designed to ensure accuracy and clarity in the disclosure and reporting of all our financial measures.
As mentioned above, our commitment is to continue to ensure the quality of the financial information we provide and that our practices meet the highest standards in the guidelines established by the CNMV and ESMA.
The company also notes the omissions noted by the Regulator in the report above, dated 21 March 2024, and that in the future, to the extent that they continue to be material, they will be included in the financial information to be reported.
| In Barcelona, 4 April 2024 |
|---|
| Nuria Martín Barnés |
| Secretary of the Board of Directors |
6
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
| Grifols, S.A. | ||
|---|---|---|
| By: | /s/ David I. Bell | |
| Name: | David I. Bell | |
| Title: | Authorized Signatory |
Date: April 4, 2024